Literature DB >> 15765541

Measurement of peak inspiratory flow with in-check dial device to simulate low-resistance (Diskus) and high-resistance (Turbohaler) dry powder inhalers in children with asthma.

Israel Amirav1, Michael T Newhouse, Yasser Mansour.   

Abstract

Drug delivery and lung deposition from a dry powder inhaler (DPI) are dependent on the peak inspiratory flow (PIF) through the DPI. Therefore, when prescribing a DPI, it is important to know whether a child is able to generate sufficient PIF through a particular device. Using a PIF meter (In-Check Dial) that mimics the internal resistance of DPIs, two commonly used devices (high-resistance Turbohaler (TH) and low-resistance Diskus (DK)) determined the PIF generated by asthmatic children through each of them. Two hundred and twenty-three children were studied, of whom 100 (mean age, 9.1 +/- 3.0 years; range, 3-15 years) were experienced with the use of a DPI (>1 month of regular DPI use), and 123 (mean, 5.5 +/- 1.9 years; range, 3-9 years) were inexperienced (no previous DPI use). All of the experienced patients generated more than 30 l/min through both devices, but a PIF of 60 l/min through the TH was obtained by only 68 (68%) of them. The age above which a minimal PIF of 30 l/min (for DK) or 60 l/min (for TH) could be achieved in new DPI users (inexperienced) was 4 years and 9 years, respectively. Even among experienced patients, many young children may not generate optimal PIFs through high-resistance DPIs. When DPI treatment is considered for young children, some devices may be successfully introduced at a younger age. It may thus be important to measure PIF in children who use a DPI or in whom DPI use is contemplated. This evaluation can be easily undertaken in the clinic with the In-Check Dial device. Copyright 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765541     DOI: 10.1002/ppul.20180

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  9 in total

Review 1.  A path to successful patient outcomes through aerosol drug delivery to children: a narrative review.

Authors:  Arzu Ari
Journal:  Ann Transl Med       Date:  2021-04

Review 2.  The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.

Authors:  Jeffry Weers; Andy Clark
Journal:  Pharm Res       Date:  2016-10-13       Impact factor: 4.200

Review 3.  A Practical Approach to Severe Asthma in Children.

Authors:  Emily E Barsky; Lauren M Giancola; Sachin N Baxi; Jonathan M Gaffin
Journal:  Ann Am Thorac Soc       Date:  2018-04

4.  Reduced Peak Inspiratory Effort through the Diskus((R)) and the Turbuhaler((R)) due to Mishandling is Common in Clinical Practice.

Authors:  Andrea S Melani; Letizia S Bracci; Marcello Rossi
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

5.  Effect of inhaler design variables on paediatric use of dry powder inhalers.

Authors:  Anne J Lexmond; Tonnis J Kruizinga; Paul Hagedoorn; Bart L Rottier; Henderik W Frijlink; Anne H de Boer
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 6.  The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not Inspiratory Flow Rates.

Authors:  Andrew R Clark; Jeffry G Weers; Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-10-31       Impact factor: 2.849

7.  Outpatient management of asthma in children.

Authors:  André Schultz; Andrew C Martin
Journal:  Clin Med Insights Pediatr       Date:  2013-04-14

8.  Performance of dry powder inhalers with single dosed capsules in preschool children and adults using improved upper airway models.

Authors:  Sandra Lindert; Antje Below; Joerg Breitkreutz
Journal:  Pharmaceutics       Date:  2014-02-06       Impact factor: 6.321

9.  Targeting inhaled aerosol delivery to upper airways in children: Insight from computational fluid dynamics (CFD).

Authors:  Prashant Das; Eliram Nof; Israel Amirav; Stavros C Kassinos; Josué Sznitman
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.